Tahithromos’s Teladoc Health TDOC Stock Holding History

Tahithromos’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16,200	Closed	-$562K	–	21
2017 Q2	$562K	Buy	+16,200	New	+$472K	0.6%	15

Other funds holding TDOC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Tiger Global Management New York $24B AUM 39.59% 1-Year Est. Return

Tahithromos's TDOC Position: Q3 2017 in Review

Tahithromos sold out of Teladoc Health (TDOC) in Q3 2017, closing a stake of 16,200 shares — an estimated $562K sold.

Tahithromos first reported a position in TDOC in Q2 2017 and held it in 1 quarter. The position peaked at $562K in Q2 2017. 178 funds tracked by Wall St. Rank hold TDOC as of Q3 2017.

Tahithromos reported no remaining Teladoc Health position as of Q3 2017 after selling out during the quarter.
Tahithromos sold 16,200 Teladoc Health shares in Q3 2017, an estimated $562K.
Tahithromos first reported a position in Teladoc Health in Q2 2017 and held it in 1 quarter.
Tahithromos's Teladoc Health position peaked at $562K in Q2 2017.
178 funds tracked by Wall St. Rank held Teladoc Health as of Q3 2017.

Based on Tahithromos's 13F filing for Q3 2017, filed 9 Nov 2017.